Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 348 participants.

Also called NCT02917031

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 348 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02917031
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Chile, Hungary, Romania, Russia, South Korea, Thailand, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02917031. Randomized; triple masking; primary purpose treatment. Start 2017-01-10 (actual); primary completion 2019-08-23 (actual). Results posted on 2021-06-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
Acronym
MEASURE-HF
Condition
Type 2 Diabetes Mellitus
Condition
Heart Failure
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo to match saxagliptin
Intervention (Drug)
Placebo to match sitagliptin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02917031
Content hash
9d91d758d7f1a937eb0755c35af5e2b96c65dc35ff2642dd0b9108eefdebd7ad